INT64843

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1996
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 19
Total Number 20
Disease Relevance 8.88
Pain Relevance 2.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serping1) extracellular region (Serping1) molecular_function (Serping1)
cellular_component (Serping1) biological_process (Serping1)
Serping1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Angina 12 100.00 Very High Very High Very High
headache 21 99.38 Very High Very High Very High
abdominal pain 9 99.36 Very High Very High Very High
ischemia 5 95.40 Very High Very High Very High
Infliximab 13 82.64 Quite High
Migraine 2 82.36 Quite High
Inflammation 6 69.04 Quite High
cytokine 3 68.00 Quite High
rheumatoid arthritis 38 66.72 Quite High
bradykinin 25 63.04 Quite High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 13 100.00 Very High Very High Very High
Headache 19 99.38 Very High Very High Very High
Abdominal Pain 9 99.36 Very High Very High Very High
Hereditary Angioedema 331 99.28 Very High Very High Very High
Disease 57 98.86 Very High Very High Very High
Cv Unclassified Under Development 5 98.52 Very High Very High Very High
Reperfusion Injury 5 97.28 Very High Very High Very High
Myocardial Infarction 6 96.04 Very High Very High Very High
Reprotox - General 1 1 96.00 Very High Very High Very High
Pressure And Volume Under Development 180 95.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Our patients may represent a form of androgen-responsive headache, which is associated with low levels of C1INH, normal levels of C1q and normal C4d/C4.
Gene_expression (levels) of C1INH associated with headache
1) Confidence 0.67 Published 1999 Journal Allergy Asthma Proc Section Abstract Doc Link 10209691 Disease Relevance 0.47 Pain Relevance 0.47
The improvement of the headache coincided with the return to normal levels of C1INH in all of our patients (pretreatment, 11 +/- 2 mg/dL versus post-treatment, 16 +/- 2 mg/dL with p < 0.001).
Gene_expression (levels) of C1INH associated with headache
2) Confidence 0.60 Published 1999 Journal Allergy Asthma Proc Section Abstract Doc Link 10209691 Disease Relevance 0.50 Pain Relevance 0.50
Differential therapy of C1-INH deficiency at the Frankfurt HAE Center
Gene_expression (deficiency) of C1-INH associated with hereditary angioedema
3) Confidence 0.53 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2920239 Disease Relevance 1.43 Pain Relevance 0.38
A diagnosis of hereditary angioedema was made based on the patient's and family's history and on decreased levels of C1 INH and complement component 4.
Gene_expression (levels) of C1 INH
4) Confidence 0.49 Published 1996 Journal J Reprod Med Section Body Doc Link 8829070 Disease Relevance 0 Pain Relevance 0
[Hereditary deficiency of C1-esterase inhibitor presenting with recurrent abdominal pain].
Gene_expression (presenting) of C1-esterase inhibitor associated with abdominal pain
5) Confidence 0.47 Published 2002 Journal Klin Padiatr Section Title Doc Link 11823949 Disease Relevance 0.28 Pain Relevance 0.18
[Hereditary deficiency of C1-esterase inhibitor presenting with recurrent abdominal pain].
Gene_expression (presenting) of C1-esterase inhibitor associated with abdominal pain
6) Confidence 0.47 Published 2002 Journal Klin Padiatr Section Title Doc Link 11823949 Disease Relevance 0.28 Pain Relevance 0.18
C1-INH levels were undetectable in two patients and low in nine patients.
Gene_expression (undetectable) of C1-INH
7) Confidence 0.45 Published 2000 Journal Turk. J. Pediatr. Section Abstract Doc Link 11105624 Disease Relevance 1.08 Pain Relevance 0.10
METHODS: The plasmatic levels of C1-INH, C3c and c4 in 30 patients affected by unstable angina, and those of 22 clinically healthy subjects (control group) were evaluated (Nefelometer Behering).
Gene_expression (levels) of C1-INH
8) Confidence 0.33 Published 2002 Journal Minerva Cardioangiol Section Body Doc Link 12473987 Disease Relevance 0.10 Pain Relevance 0
[Evaluation of C3c, C4 and C1-esterase inhibitor (C1-INH) during unstable angina].
Gene_expression ([Evaluation) of C1-INH associated with angina
9) Confidence 0.29 Published 2002 Journal Minerva Cardioangiol Section Title Doc Link 12473987 Disease Relevance 0.38 Pain Relevance 0.23
[Evaluation of C3c, C4 and C1-esterase inhibitor (C1-INH) during unstable angina].
Gene_expression ([Evaluation) of C1-esterase associated with angina
10) Confidence 0.29 Published 2002 Journal Minerva Cardioangiol Section Title Doc Link 12473987 Disease Relevance 0.37 Pain Relevance 0.23
The aim of this study is to investigate the plasmatic levels of some complement components (C3c, C4 and C1-INH) during unstable angina (C1-INH) and their different concentrations in relation to the different myocardial areas affected by ischemia.
Spec (investigate) Gene_expression (levels) of C1-INH associated with angina and ischemia
11) Confidence 0.26 Published 2002 Journal Minerva Cardioangiol Section Abstract Doc Link 12473987 Disease Relevance 0.46 Pain Relevance 0.22
RESULTS: No statistically significant differences were found in plasmatic levels of C3c, C4 and C1-INH between the group of patients and the control group.
Gene_expression (levels) of C1-INH
12) Confidence 0.26 Published 2002 Journal Minerva Cardioangiol Section Body Doc Link 12473987 Disease Relevance 0.08 Pain Relevance 0
For three other IFN response genes (Mx2, OAS2, and SERPING1), a trend (P = approximately 0.06, data not shown) was observed toward increased expression in the poor responder patients.
Gene_expression (expression) of SERPING1
13) Confidence 0.25 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875639 Disease Relevance 0.19 Pain Relevance 0.17
The Bonferroni correction was used for the analysis of C1-INH (antigen and activity) and C4 levels in the treated and untreated patients.
Gene_expression (levels) of C1-INH
14) Confidence 0.13 Published 2008 Journal Arch Immunol Ther Exp (Warsz) Section Body Doc Link PMC2734250 Disease Relevance 0.68 Pain Relevance 0
It should be stressed that the disease symptom score was usually higher in individuals in whom C1-INH activity did not exceed 10% (median: 5, mean: 4.5) than in persons with this activity over 10% (median: 3, mean: 3.4; p<0.05).
Gene_expression (activity) of C1-INH associated with disease
15) Confidence 0.11 Published 2008 Journal Arch Immunol Ther Exp (Warsz) Section Body Doc Link PMC2734250 Disease Relevance 0.25 Pain Relevance 0
There was a strong positive correlation between C1-INH antigen concentration and C1-INH activity (Spearman’s correlation test, r=0.57, p<0.01) and negative correlations between these and the score of severity of symptoms (r= -0.33, p=0.01 and r= -0.31, p=0.02), respectively.
Gene_expression (concentration) of C1-INH
16) Confidence 0.11 Published 2008 Journal Arch Immunol Ther Exp (Warsz) Section Body Doc Link PMC2734250 Disease Relevance 0.16 Pain Relevance 0
The Bonferroni correction was used for the analysis of C1-INH (antigen and activity) and C4 levels in the treated and untreated patients.
Gene_expression (levels) of C1-INH
17) Confidence 0.11 Published 2008 Journal Arch Immunol Ther Exp (Warsz) Section Body Doc Link PMC2734250 Disease Relevance 0.68 Pain Relevance 0
Assessment of C1-INH and C4
Gene_expression (Assessment) of C1-INH
18) Confidence 0.11 Published 2008 Journal Arch Immunol Ther Exp (Warsz) Section Body Doc Link PMC2734250 Disease Relevance 0.22 Pain Relevance 0
There was a strong positive correlation between C1-INH antigen concentration and C1-INH activity (Spearman’s correlation test, r=0.57, p<0.01) and negative correlations between these and the score of severity of symptoms (r= -0.33, p=0.01 and r= -0.31, p=0.02), respectively.
Gene_expression (concentration) of C1-INH
19) Confidence 0.11 Published 2008 Journal Arch Immunol Ther Exp (Warsz) Section Body Doc Link PMC2734250 Disease Relevance 0.16 Pain Relevance 0
Medication to relieve acute edematous attacks should also be provided (such as C1-INH) - regardless of whether or not the patient has already experienced a severe episode previously.

4.2 Management of UAE event

Neg (not) Gene_expression (provided) of C1-INH associated with pressure and volume under development
20) Confidence 0.07 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2920238 Disease Relevance 1.12 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox